Table 4.
Lipid and Inflammatory Measures at Week 0 and Week 16
| Measurement† | Week | MD Group Mean ± SD |
Within Group Δ p-value |
Week | FB Group Mean ± SD |
Within Group Δ p-value |
Between Group Δ p-value |
|---|---|---|---|---|---|---|---|
| Total Cholesterol | 0 (n = 39) | 191.2 ± 39.5 | p = 0.841 | 0 (n = 40) | 187.5 ± 43.0 | p = 0.687 | p = 0.409 |
| (mg/dl) | 16 (n = 25) | 181.3 ± 40.4 | 16 (n = 20) | 184.9 ± 45.9 | |||
| HDL | 0 (n = 39) | 52.0 ± 16.0 | p = 0.843 | 0 (n = 40) | 51.8 ± 18.0 | p = 0.261 | p = 0.62 |
| (mg/dl) | 16 (n = 25) | 51.6 ± 11.3 | 16 (n = 20) | 48.2 ± 11.3 | |||
| LDL | 0 (n = 39) | 117.3 ± 31.8 | p = 0.253 | 0 (n = 40) | 108.8 ± 32.0 | p = 0.779 | p = 0.396 |
| (mg/dl) | 16 (n = 25) | 111.4 ± 34.4 | 16 (n = 19) | 110.7 ± 37.6 | |||
| VLDL | 0 (n = 38) | 21.9 ± 13.0 | p = 0.026 | 0 (n = 37) | 27.9 ± 17.9 | p = 0.01 | p = 0.652 |
| (mg/dl) | 16 (n = 24) | 17.5 ± 9.8 | 16 (n = 20) | 26.1 ± 16.4 | |||
| Triglycerides | 0 (n = 39) | 109.2 ± 63.7 | p = 0.061 | 0 (n = 40) | 134.7 ± 86.8 | p = 0.009 | p = 0.502 |
| (mg/dl) | 16 (n = 25) | 91.8 ± 52.7 | 16 (n = 20) | 130.4 ± 81.6 | |||
| CRP | 0 (n = 38) | 5.7 ± 4.8 | p = 0.200 | 0 (n = 39) | 7.1 ± 9.4 | p = 0.018 | p = 0.45 |
| (mg/L) | 16 (n = 25) | 3.6 ± 2.9 | 16 (n = 20) | 4.3 ± 4.7 | |||
| ULP | 0 (n = 44) | 6.1 ± 2.2 | p = 0.684 | 0 (n = 44) | 5.5 ± 1.7 | p = 0.538 | p = 0.973 |
| (micromol/g creatinine) | 16 (n = 27) | 6.2 ± 2.2 | 16 (n = 20) | 5.3 ± 2.4 |
Δ = Change from baseline to 16 weeks.
† = Secondary outcomes.